ANNALS OF NUCLEAR MEDICINE, cilt.25, sa.6, ss.425-431, 2011 (SCI-Expanded)
This study aimed to assess the outcome of high-dose In-111 octreotide treatment and efficacy of long-acting Sandostatin LAR in patients with disseminated neuroendocrine tumors.